Cancer Research Technology Ltd. and Merck KGaA have jointly patented tricyclic heterocycles acting as transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors.
Bioray Pharmaceutical Co. Ltd.’s IND application for BRY-812, a novel antibody-drug conjugate (ADC) targeting human LIV-1 for the treatment of advanced malignant tumors, has been accepted by the China National Medical Products Administration (NMPA).
Antengene Corp. Ltd.'s Claudin 18.2 antibody-drug conjugate (ADC) ATG-022 has been granted two orphan drug designations consecutively by the FDA for the treatment of gastric cancer and pancreatic cancer.
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by a chromosomal translocation that results in the generation of the BCR-ABL1 oncogene, which encodes the chimeric BCR-ABL1 protein with tyrosine kinase activity. Allosteric tyrosine kinase inhibitors (TKIs) represent an improvement of 2-fold in efficacy over standard inhibitors and are better tolerated.
Coherent Biopharma Co. Ltd. raised $100 million in series B and B+ financing rounds to step up its efforts to develop its bi-targeting ligand-drug conjugate (Bi-XDC) drugs and get them to market. Suzhou, China-based Coherent plans to use its newly expanded war chest to support the clinical trials of three candidates, CBP-1008, CBP-1018 and CBP-1019, as well as an IND application for CBP-8008 in China and the U.S., the company told BioWorld.
C-C Chemokine receptor type 6 (CCR6) antagonists have been reported in a recent Idorsia Pharmaceuticals Ltd. patent as potentially useful for the treatment of cancer, autoimmune disease and inflammatory disorders.
Researchers from Henan University of Chinese Medicine have reported the discovery and preclinical evaluation of new histone lysine-specific demethylase 1 (LSD1) inhibitors as potential anticancer candidates.
Rain Oncology Inc.’s only asset failed a pivotal phase III study for treating dedifferentiated liposarcoma, casting shadows on the future of the small molecule and the company’s direction. Milademetan, an oral inhibitor of the MDM2-p53 complex that reactivates p53, missed the Mantra study’s primary endpoint of progression-free survival compared to the standard of care treatment, Yondelis (trabectedin, Johnson & Johnson/Pharmamar SA).
A Voronoi Bio Inc. and Voronoi Inc. patent describes platelet-derived growth factor receptor (PDGFR), mast/stem cell growth factor receptor kit (KIT; c-Kit; CD117) and their mutant inhibitors reported to be useful for the treatment of cancer, fibrosis, neurological diseases, atherosclerosis, and pulmonary hypertension.
Researchers from City of Hope discussed preclinical data for CD33-targeted chimeric antigen receptor (CAR) T cells being developed for the treatment of acute myeloid leukemia (AML).
RSS
.webp?height=488&t=1670008838&width=650 "Acute myeloid leukemia")